FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury

被引:43
作者
Dragun, D
Böhler, T
Nieminen-Kelmä, M
Waiser, J
Schneider, W
Haller, H
Luft, FC
Budde, K
Neumayer, HH
机构
[1] Humboldt Univ, Fac Med Charite, Dept Nephrol, Berlin, Germany
[2] Hannover Med Sch, D-3000 Hannover, Germany
[3] Helios Klinikum Berlin Buch, Inst Pathol, Berlin, Germany
关键词
neutrophils; inflammation; endothelium; lymphocyte homing; monocytes;
D O I
10.1111/j.1523-1755.2004.00478.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. A novel immunomodulator, FTY720, modulates lymphocyte migration to injured tissues via enhanced lymphocyte sequestration to secondary lymphoid organs. We tested whether or not single-dose FTY720 (0.5 mg/kg) pretreatment rescues renal grafts from post-transplant preservation/ reperfusion injury. Methods. Rat renal grafts were cold-preserved in University of Wisconsin (UW) solution for 4 hours and then transplanted into syngeneic or allogeneic recipients that received a single dose of FTY720 24 hours before transplantation. Flow cytometry analysis of peripheral blood and lymph nodes was performed to confirm the biologic effect of FTY720. Grafts were harvested after 24 hours. Renal sections were examined histologically and stained for intracellular adhesion molecule-1 (ICAM-1), vascular cellular adhesion molecule-1 (VCAM-1), platelet endothelial cellular adhesion molecule-1 (PECAM-1), major histocompatibility complex (MHC) class II, and inflammatory cells. Interleukin-1 (IL-1) production was determined in renal protein extracts. Results. FTY720 pretreatment significantly increased CD3(+) T-cell sequestration to lymph nodes in the face of peripheral lymphopenia. Isografts and allografts from the FTY720-treated groups did not develop increased creatinine (0.55 +/- 0.12 in isografts and 0.62 +/- 0. 08 mg/dL in allografts), compared with vehicle controls (2.28 +/- 0.20 in isografts and 2.24 +/- 0.18 mg/dL in allografts). Kidneys from FTY720-treated groups also showed lower acute tubular damage scores. Furthermore, FTY720 decreased neutrophil influx, although circulating neutrophils were unchanged. FTY720 also prevented postischemic IL-1 intragraft production not affecting infiltration with recipient ED-1(+) macrophages and MHC class II-positive cells. Expression of ICAM-1, VCAM-1, and PECAM did not differ among groups. Conclusion. FTY720 ameliorated morphologic and functional consequences of post-transplant reperfusion injury. Thus, FTY720-induced peripheral T-cell absence may influence intragraft IL-1 production and neutrophil infiltration, despite proadhesive endothelial properties. FTY720 may broaden the utility in renal transplantation as a pretreatment strategy against preservation/reperfusion injury.
引用
收藏
页码:1076 / 1083
页数:8
相关论文
共 31 条
[1]   OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long-term survival [J].
Abramowicz, D ;
Norman, DJ ;
Vereerstraeten, P ;
Goldman, M ;
DePauw, L ;
Vanherweghem, JL ;
Kinnaert, P ;
Kahana, L ;
Stuart, FP ;
Thistlethwaite, JR ;
Shield, CF ;
Monaco, A ;
Wu, SC ;
Haverty, TP .
KIDNEY INTERNATIONAL, 1996, 49 (03) :768-772
[2]   The immune modulator FTY720 targets sphingosine 1-phosphate receptors [J].
Brinkmann, V ;
Davis, MD ;
Heise, CE ;
Albert, R ;
Cottens, S ;
Hof, R ;
Bruns, C ;
Prieschl, E ;
Baumruker, T ;
Hiestand, P ;
Foster, CA ;
Zollinger, M ;
Lynch, KR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21453-21457
[3]   FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity [J].
Brinkmann, V ;
Lynch, KR .
CURRENT OPINION IN IMMUNOLOGY, 2002, 14 (05) :569-575
[4]   FTY720: Altered lymphocyte traffic results in allograft protection. [J].
Brinkmann, V ;
Pinschewer, DD ;
Feng, L ;
Chen, S .
TRANSPLANTATION, 2001, 72 (05) :764-769
[5]   Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients [J].
Budde, K ;
Schmouder, RL ;
Nashan, B ;
Brunkhorst, R ;
Lücker, PW ;
Mayer, T ;
Brookman, L ;
Nedelman, J ;
Skerjanec, A ;
Böhler, T ;
Neumayer, HH .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (07) :846-854
[6]  
Budde K, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341073
[7]  
Burne MJ, 2001, J LEUKOCYTE BIOL, V70, P192
[8]   Identification of the CD4+ T cell as a major pathogenic factor in ischemic acute renal failure [J].
Burne, MJ ;
Daniels, F ;
El Ghandour, A ;
Mauiyyedi, S ;
Colvin, RB ;
O'Connell, MP ;
Rabb, H .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (09) :1283-1290
[9]   The role of adhesion molecules and T cells in ischemic renal injury [J].
Burne-Taney, MJ ;
Rabb, H .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2003, 12 (01) :85-90
[10]   Immunosuppressive medications for renal transplantation: A multiple choice question [J].
Danovitch, GM .
KIDNEY INTERNATIONAL, 2001, 59 (01) :388-402